Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2014; 20(26): 8599-8605
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8599
Published online Jul 14, 2014. doi: 10.3748/wjg.v20.i26.8599
Endoscopic ultrasound-guided fine-needle aspiration for suspected malignancies adjacent to the gastrointestinal tract
Pietro Gambitta, Antonio Armellino, Edoardo Forti, Unità di Chirurgia Endoscopica ed Ecoendoscopia Ospedale Niguarda Ca’ Granda, 20162 Milano, Italy
Maurizio Vertemati, Dipartimento di Scienze Biomediche e Cliniche “L. Sacco”, Università degli Studi di Milano, 20157 Milano, Italy
Paola Enrica Colombo, Servizio di Fisica Sanitaria, Ospedale Niguarda Ca’ Granda, 20162 Milano, Italy
Paolo Aseni, HPB and Transplantation Surgery, Ospedale Niguarda Ca’ Granda, 20162 Milano, Italy
Author contributions: Gambitta P and Aseni P contributed equally to this work by designing the study, performing the research, and writing the paper; Gambitta P, Armellino A, Forti E and Aseni P performed the research; Forti E, Vertemati M, and Colombo PE analyzed data; Vertemati M and Aseni P reviewed and edited the manuscript.
Correspondence to: Paolo Aseni, MD, HPB and Transplantation Surgery, Ospedale Niguarda Ca’ Granda, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. paoloaseni@gmail.com
Telephone: +38-2-64442252 Fax: +39-2-64442893
Received: January 9, 2014
Revised: March 7, 2014
Accepted: April 21, 2014
Published online: July 14, 2014
Revised: March 7, 2014
Accepted: April 21, 2014
Published online: July 14, 2014
Core Tip
Core tip: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become paramount in establishing a diagnosis for all suspected malignant lesions of the gastrointestinal tract. Due to its increasing demand, the diagnostic yield of EUS-FNA and the length of time to determine a definitive cytological diagnosis may not be satisfactory in clinical practice. We found that EUS-FNA, when combined with the clinical evaluation of malignancy risk, was associated with a reliable level of accuracy. When prioritized for those patients with the highest clinical suspicion of cancer risk, EUS-FNA provides a shorter time to diagnosis for those patients with a higher cancer risk who can benefit from early therapy.